Eli Lilly Raises Sales Forecast As Weight Loss Drug Demand Soars. Its Stock is Climbing
- Posted on August 5, 2026
- By International Business Times
- 0 Views
- 1 min read
In brief
Generating AI summary…
Eli Lilly Raises Sales Forecast As Weight Loss Drug Demand Soars. Its Stock is Climbing
Eli Lilly posted stronger-than-expected second-quarter earnings and revenue, boosted by surging demand for Zepbound and Mounjaro, while its newly launched obesity pill Foundayo made its first contribution to quarterly sales.